Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies

MLA

Michael Scordo, et al. “Outcomes in Patients with DLBCL Treated with Commercial CAR T Cells Compared with Alternate Therapies.” Blood Advances, vol. 4, Oct. 2020, pp. 4669–78. EBSCOhost, https://doi.org/10.1182/bloodadvances.2020002118.

APA

Michael Scordo, Gunjan L. Shah, Ariela Noy, Andrew D. Zelenetz, Lorenzo Falchi, Sean M. Devlin, Erel Joffe, Gottfried von Keudell, David Sermer, Miguel-Angel Perales, Craig S. Sauter, Alison J. Moskowitz, Paul A. Hamlin, Anas Younes, Caleb Ho, Mari Lynne Silverberg, Aishat Afuye, Jessica Flynn, Audrey Hamilton, … David J. Straus. (2020). Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies. Blood Advances, 4, 4669–4678. https://doi.org/10.1182/bloodadvances.2020002118

Chicago

Michael Scordo, Gunjan L. Shah, Ariela Noy, Andrew D. Zelenetz, Lorenzo Falchi, Sean M. Devlin, Erel Joffe, et al. 2020. “Outcomes in Patients with DLBCL Treated with Commercial CAR T Cells Compared with Alternate Therapies.” Blood Advances 4 (October): 4669–78. doi:10.1182/bloodadvances.2020002118.